Business Context and Reporting Period
This filing is a Form 10-Q for AVI BioPharma, Inc., the historical predecessor associated with the requested Sarepta Therapeutics record, for the quarter and nine months ended September 30, 2011. The company was a development-stage biopharmaceutical focused on RNA-based therapeutics, including eteplirsen for Duchenne muscular dystrophy and antiviral candidates for Ebola, Marburg, and influenza. The filing was signed November 8, 2011.
Financial Results and Key Metrics
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $7.5 million | $8.7 million | $33.4 million | $13.9 million |
| Research and development expense | $15.6 million | $9.1 million | $48.2 million | $22.1 million |
| General and administrative expense | $3.2 million | $3.4 million | $12.2 million | $11.0 million |
| Operating loss | $11.3 million | $3.8 million | $26.9 million | $19.2 million |
| Net loss | $4.0 million | $7.3 million | $0.9 million | $24.5 million |
| Loss per share | $0.03 | $0.07 | $0.01 | $0.22 |
Revenue was derived substantially from U.S. government research contracts rather than product sales. The company had no material commercial product revenue and had accumulated losses of $308.6 million since inception.
Q3 operating margin was approximately negative 150%, and nine-month operating margin was approximately negative 81%. The reported improvement in net loss primarily reflected a $7.1 million quarterly and $25.6 million nine-month non-cash gain from revaluing warrant liabilities.
Cash and cash equivalents were $46.4 million at September 30, 2011, compared with $33.6 million at December 31, 2010. Operating activities used $18.0 million during the first nine months, investing activities used $1.5 million, and financing activities provided $32.3 million, primarily from the April 2011 equity offering.
Total debt was approximately $1.9 million, including $84,000 due within one year. Current liabilities were $26.5 million, including a $12.9 million warrant liability and $3.3 million of deferred revenue. The company stated that available cash, excluding future optional government funding, was expected to finance operations for at least the next 12 months.
Material Changes Versus the Prior Comparable Period
- Q3 revenue declined 14% year over year because lower H1N1 and legacy government-contract activity more than offset higher Ebola and Marburg revenue.
- Nine-month revenue increased 140%, primarily because of $29.8 million of revenue recognized under the July 2010 Ebola and Marburg agreement versus $2.7 million in the prior-year period.
- Research and development expense increased 72% in Q3 and 118% for the nine-month period, driven by greater spending on the Duchenne muscular dystrophy program, Ebola and Marburg development, and other proprietary programs.
- The company initiated a Phase II U.S. trial of eteplirsen in August 2011 and targeted entry into a pivotal trial in the second half of 2012.
- Shareholders’ equity improved to $31.8 million from a $2.8 million deficit at December 31, 2010, primarily reflecting the April equity financing and the reduction in the warrant liability.
- Common shares outstanding increased to approximately 135.7 million from approximately 112.4 million at year-end 2010. The company also had 14.9 million vested or expected-to-vest option shares and 29.2 million outstanding warrant shares.
Guidance, Outlook, Risks, and Unusual Items
Management expected continued operating losses for several years and anticipated higher research and development spending as eteplirsen advanced toward later-stage clinical development. No specific revenue or earnings guidance was provided.
As of September 30, 2011, ongoing government contracts provided up to $126.5 million of current-segment funding, of which $39.6 million had been recognized. The company was potentially eligible for up to an additional $161.5 million if the Department of Defense exercised all options under the Ebola and Marburg program. These amounts were contingent on government funding, contract performance, and option exercises.
- Revenue and research spending could fluctuate materially based on the timing of government-contract activities, and the government could delay funding or terminate contracts for convenience.
- The company had not generated product-sales revenue and would require additional capital over time; future financings could dilute shareholders.
- Clinical and regulatory risks included failure to establish an effective eteplirsen dose, unsuccessful clinical trials, delays, manufacturing constraints, and inability to obtain FDA approval.
- The Ebola and Marburg programs depended on the uncertain and relatively untested FDA Animal Rule pathway.
- The company disclosed potential intellectual-property challenges involving Prosensa patent rights in Europe and Japan that could impair commercialization of eteplirsen if unresolved adversely.
- Warrant liabilities were classified as derivative liabilities and remeasured through earnings using Level 3 valuation inputs, creating substantial non-cash earnings volatility.
- Former senior executives received separation payments and accelerated or extended option rights during the nine-month period.
- No material legal proceedings were pending as of the filing date, although ordinary-course claims remained possible.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for AVI BioPharma, Inc., not an entity named Sarepta Therapeutics, Inc.
- Verify the sustainability and timing of U.S. government contract revenue, including the status of unrecognized funding and discretionary options.
- Assess cash runway against the $18.0 million nine-month operating cash burn and planned increases in DMD and clinical-development spending.
- Review the April 2011 equity financing, outstanding options and warrants, and potential dilution from future capital raises.
- Evaluate clinical progress, dosing results, regulatory strategy, and the stated second-half 2012 pivotal-trial objective for eteplirsen.
- Monitor the Prosensa patent opposition and potential Japanese invalidation proceedings.
- Separate operating performance from the $25.6 million year-to-date non-cash gain on warrant revaluation.